DelveInsight's Underactive Bladder Syndrome Market Insights report includes a comprehensive understanding of current ...

Anktiva, also known as nogapendekin alfa inbakicept, is a new cancer therapy that boosts the immune system to target cancer ...

The Saudi Food and Drug Authority (SFDA) has granted conditional approval for Anktiva, a groundbreaking cancer therapy, for ...

West Tennessee Healthcare is pleased to announce a new treatment option for people living with urge urinary incontinence (UUI ...

Saudi Arabia leads the way as the first country to grant conditional approval for Anktiva, a groundbreaking treatment for ...

Saudi Gazette reportRIYADH — The Saudi Food and Drug Authority (SFDA) has granted conditional approval for Anktiva (nogapendekin alfa inbakicept) in combination with immunotherapy for adult patients ...

The underactive bladder syndrome market is expected to grow steadily, driven by an aging global population and rising prevalence of neurogenic and chronic conditions affecting bladder function.

I'm trained to treat conditions I used to see mainly in older patients - but now it's all teenagers and people in their early ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene ...

Harry Powell has been battling chronic kidney disease since he was just seven days old ...